kentucky tirzepatide class action Zepbound Lawsuit [2026] kentucky glp-1 ileus attorney legal

SURPASS-2 trial confirmed that gastrointestinal adverse events with tirzepatide were consistent with the GLP-1 receptor agonist class, mostly mild to moderate, and occurred during the escalation period with both tirzepatide and the comparator drug semaglutide

goal 23 semisoft stools per day) plus albumin (1.5 g/kg/day) or lactulose alone, and treatment was continued until recovery of HE or for a maximum of 10 days

It may aid cognitive function, especially in older adults

#GLP1 #HealthcareNews #GLP1Journey #HealthNews #Semaglutide #Tirzepatide | QuickMD- Addiction Treatment, Weight Loss, & Urgent Care via Telemedicine